⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899 | 1.00 | — | — | |
| SCHEMBL416473 | 1.00 | — | — | |
| SCHEMBL14491007 | 0.93 | — | — | |
| SCHEMBL27497957 | 0.85 | ACHE (0.31) | — | |
| SCHEMBL19093842 | 0.84 | ALDH1A1 (0.37) | — | |
| SCHEMBL631210 | 0.84 | — | — | |
| SCHEMBL13021 | 0.84 | — | — | |
| SCHEMBL2184846 | 0.84 | — | — | |
| SCHEMBL8462652 | 0.81 | — | — | |
| SCHEMBL22225552 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-4129999-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents Of The University Of Michigan (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | Wuxi Life Fountain Biotech Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022143602-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-07-07 | — | — | WO | disclosed |
| EP-3672594-B1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| EP-3672595-B1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2018027097-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2017192485-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-8975250-B2 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | SANOFI (FR) | 2015-03-10 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |